-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nonsteroidal Antiinflammatory Drugs (NSAIDs) are a class of anti-inflammatory drugs that do not contain a steroid structure.
Since aspirin was first synthesized in 1898, more than 100 types and thousands of brands have been on the market for more than 100 years
.
Non-steroidal anti-inflammatory drugs (NSAIDs) are a combination of unrelated organic acids with analgesic, anti-inflammatory and antipyretic properties
.
NSAID is an inhibitor of cyclooxygenase, which directly inhibits the biosynthesis of prostaglandin and thromboxane from arachidonic acid
.
There are two forms of cyclooxygenase (COX), COX-1 is the constitutive form of the enzyme, and COX-2 is the form that is induced when inflammation is present
.
Therefore, COX-2 inhibition is believed to be related to at least some of the analgesic, anti-inflammatory and antipyretic properties of NSAIDs, while COX-1 inhibition is believed to produce certain toxic effects, especially toxicity to the gastrointestinal tract
.
Most NSAIDs currently in clinical use inhibit both COX-1 and COX-2, although selective COX-2 inhibitors (such as celecoxib) have been used
.
NSAIDs are used to relieve mild to moderate pain, low-grade fever symptoms and for acute and chronic inflammatory diseases such as osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis
.
Indomethacin and certain other NSAIDs are used to close patent ducts in preterm infants
.
Certain NSAIDs are used topically to relieve muscle and rheumatic pain, and some are used in ophthalmic preparations to treat ophthalmic inflammatory diseases
.
Today we will talk about Aceclofenac in NSAIDs
.
Part 1 Structural Information of Aceclofenac Figure 1.
Structural formula of Aceclofenac, picture source: Drug Data Molecular formula: C16H13CI2NO4 Molecular weight: 354.
18 CAS number: 89796-99-6 Figure 2.
Free state parameters of Aceclofenac, Image source: Yaodu data Part 2 Overview of the basic information of the drug
.
Information listed on January 1, 1992, aceclofenac eligible for EU Drug Administration approved the first; February 6, 2005, the Chinese State Drug Administration approved NMPA, sold by Guangzhou Baiyunshan Pharmaceutical Co.
, Ltd.
Guanghua
.
(National Medicine Standard H20050479) 1) Ankylosing spondylitis was approved by the China National Medical Products Administration NMPA on February 6, 2005, and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
, Ltd.
It is an oral capsule (intestinal) Soluble), the specification is 50mg
.
2) Rheumatoid Arthritis On February 6, 2005, the drug was approved by the National Medical Products Administration of China NMPA and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
, Ltd.
It is an oral capsule (enteric-coated) with a specification of 50 mg
.
3) Osteoarthritis On February 6, 2005, the drug was approved by the China National Medical Products Administration NMPA and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
, Ltd.
It is an oral capsule (enteric-coated) with a specification of 50 mg
.
Part 3 Pharmacokinetics The gastrointestinal absorption of aceclofenac is very good, and the peak plasma concentration is reached 1~3h after a single dose of oral administration. .
More than 99% of aceclofenac is bound to plasma proteins
.
The plasma elimination half-life is about 4h
.
About two-thirds of a single dose is mainly excreted in the urine as hydroxyl metabolites
.
Part 4 Adverse reactions and precautions When using aceclofenac to relieve the pain and inflammation of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, it is necessary to consider that aceclofenac has been determined to be contraindicated in the following patients: lack Blood heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (classification II-IV)
.
Any important risk factors for cardiovascular events need to be considered, such as hypertension, hyperlipidemia, diabetes, etc.
, before aceclofenac treatment can be started
.
Aceclofenac, as a non-steroidal anti-inflammatory drug (NSAID), has been approved to relieve pain and inflammation of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis
.
Aceclofenac itself has almost no pharmacological activity, and its main mode of action is through its metabolites, including diclofenac
.
In June 2013, a European regulatory agency review concluded that the risk of arterial thrombosis (myocardial infarction, stroke) of diclofenac is higher than other NSAIDs
.
Precautions for all non-steroidal anti-inflammatory drugs: Based on the evaluation of each patient’s individual risk factors (including any history of cardiovascular and gastrointestinal diseases), decide to prescribe NSAID; use it in the shortest duration required to control symptoms The lowest effective dose; periodically reassess the patient's need for symptom relief and response to treatment
.
This article is only for academic content and does not constitute any medication advice! References: 1.
Drug crossing data 2.
Martindale Drug Dictionary (Original 35th edition) 3.
https:// -line-with-diclofenac-and-cox-2-inhibitors
Since aspirin was first synthesized in 1898, more than 100 types and thousands of brands have been on the market for more than 100 years
.
Non-steroidal anti-inflammatory drugs (NSAIDs) are a combination of unrelated organic acids with analgesic, anti-inflammatory and antipyretic properties
.
NSAID is an inhibitor of cyclooxygenase, which directly inhibits the biosynthesis of prostaglandin and thromboxane from arachidonic acid
.
There are two forms of cyclooxygenase (COX), COX-1 is the constitutive form of the enzyme, and COX-2 is the form that is induced when inflammation is present
.
Therefore, COX-2 inhibition is believed to be related to at least some of the analgesic, anti-inflammatory and antipyretic properties of NSAIDs, while COX-1 inhibition is believed to produce certain toxic effects, especially toxicity to the gastrointestinal tract
.
Most NSAIDs currently in clinical use inhibit both COX-1 and COX-2, although selective COX-2 inhibitors (such as celecoxib) have been used
.
NSAIDs are used to relieve mild to moderate pain, low-grade fever symptoms and for acute and chronic inflammatory diseases such as osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis
.
Indomethacin and certain other NSAIDs are used to close patent ducts in preterm infants
.
Certain NSAIDs are used topically to relieve muscle and rheumatic pain, and some are used in ophthalmic preparations to treat ophthalmic inflammatory diseases
.
Today we will talk about Aceclofenac in NSAIDs
.
Part 1 Structural Information of Aceclofenac Figure 1.
Structural formula of Aceclofenac, picture source: Drug Data Molecular formula: C16H13CI2NO4 Molecular weight: 354.
18 CAS number: 89796-99-6 Figure 2.
Free state parameters of Aceclofenac, Image source: Yaodu data Part 2 Overview of the basic information of the drug
.
Information listed on January 1, 1992, aceclofenac eligible for EU Drug Administration approved the first; February 6, 2005, the Chinese State Drug Administration approved NMPA, sold by Guangzhou Baiyunshan Pharmaceutical Co.
, Ltd.
Guanghua
.
(National Medicine Standard H20050479) 1) Ankylosing spondylitis was approved by the China National Medical Products Administration NMPA on February 6, 2005, and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
, Ltd.
It is an oral capsule (intestinal) Soluble), the specification is 50mg
.
2) Rheumatoid Arthritis On February 6, 2005, the drug was approved by the National Medical Products Administration of China NMPA and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
, Ltd.
It is an oral capsule (enteric-coated) with a specification of 50 mg
.
3) Osteoarthritis On February 6, 2005, the drug was approved by the China National Medical Products Administration NMPA and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
, Ltd.
It is an oral capsule (enteric-coated) with a specification of 50 mg
.
Part 3 Pharmacokinetics The gastrointestinal absorption of aceclofenac is very good, and the peak plasma concentration is reached 1~3h after a single dose of oral administration. .
More than 99% of aceclofenac is bound to plasma proteins
.
The plasma elimination half-life is about 4h
.
About two-thirds of a single dose is mainly excreted in the urine as hydroxyl metabolites
.
Part 4 Adverse reactions and precautions When using aceclofenac to relieve the pain and inflammation of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, it is necessary to consider that aceclofenac has been determined to be contraindicated in the following patients: lack Blood heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (classification II-IV)
.
Any important risk factors for cardiovascular events need to be considered, such as hypertension, hyperlipidemia, diabetes, etc.
, before aceclofenac treatment can be started
.
Aceclofenac, as a non-steroidal anti-inflammatory drug (NSAID), has been approved to relieve pain and inflammation of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis
.
Aceclofenac itself has almost no pharmacological activity, and its main mode of action is through its metabolites, including diclofenac
.
In June 2013, a European regulatory agency review concluded that the risk of arterial thrombosis (myocardial infarction, stroke) of diclofenac is higher than other NSAIDs
.
Precautions for all non-steroidal anti-inflammatory drugs: Based on the evaluation of each patient’s individual risk factors (including any history of cardiovascular and gastrointestinal diseases), decide to prescribe NSAID; use it in the shortest duration required to control symptoms The lowest effective dose; periodically reassess the patient's need for symptom relief and response to treatment
.
This article is only for academic content and does not constitute any medication advice! References: 1.
Drug crossing data 2.
Martindale Drug Dictionary (Original 35th edition) 3.
https:// -line-with-diclofenac-and-cox-2-inhibitors
